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ABSTRACT
The tumor suppressor Spred2 (Sprouty-related EVH1 domain-2) induces cell 
death in a variety of cancers. However, the underlying mechanism remains to be 
elucidated. Here we show that Spred2 induces caspase-independent but autophagy-
dependent cell death in human cervical carcinoma HeLa and lung cancer A549 cells. 
We demonstrate that ectopic Spred2 increased both the conversion of microtubule-
associated protein 1 light chain 3 (LC3), GFP-LC3 puncta formation and p62/SQSTM1 
degradation in A549 and HeLa cells. Conversely, knockdown of Spred2 in tumor cells 
inhibited upregulation of autophagosome maturation induced by the autophagy 
inducer Rapamycin, which could be reversed by the rescue Spred2. These data 
suggest that Spred2 promotes autophagy in tumor cells. Mechanistically, Spred2 
co-localized and interacted with LC3 via the LC3-interacting region (LIR) motifs in 
its SPR domain. Mutations in the LIR motifs or deletion of the SPR domain impaired 
Spred2-mediated autophagosome maturation and tumor cell death, indicating that 
functional LIR is required for Spred2 to trigger tumor cell death. Additionally, Spred2 
interacted and co-localized with p62/SQSTM1 through its SPR domain. Furthermore, 
the co-localization of Spred2, p62 and LAMP2 in HeLa cells indicates that p62 may 
be involved in Spred2-mediated autophagosome maturation. Inhibition of autophagy 
using the lysosomal inhibitor chloroquine, reduced Spred2-mediated HeLa cell death. 
Silencing the expression of autophagy-related genes ATG5, LC3 or p62 in HeLa and 
A549 cells gave similar results, suggesting that autophagy is required for Spred2-
induced tumor cell death. Collectively, these data indicate that Spred2 induces tumor 
cell death in an autophagy-dependent manner.
INTRODUCTION
Sprouty-related EVH1 domain (Spred) proteins 
function as negative regulators of growth factors, cytokines 
and chemokine-induced ERK (extracellular-regulated 
kinase) activation by binding to Ras and Raf-1 [1–3]. 
Spreds (Spred1, 2 and 3) contain an N-terminal Ena/VASP 
homology 1 domain (EVH1), a central c-Kit binding 
domain (KBD) and a C-terminal cysteine-rich Sprouty-
related domain (SPR) that is shared with the Sprouty 
proteins [1, 4]. Several studies, including our previous 
work, have reported that the EVH1 and SPR domains 
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play critical roles in the Spred-mediated inhibitory effect 
on ERK activation [1, 3, 5–9], although the KBD region 
is dispensable [4]. Accumulating evidence indicates that 
Spreds function as a tumor suppressor in tumor development 
and progression [10–14]. Expression of Spred1 and/or 
Spred2 was frequently reduced in hepatocellular carcinoma 
and prostate cancer [15, 16], while decreased Spred 
levels were associated with increased tumor invasion and 
metastasis [16, 17]. Moreover, in vitro and in vivo models 
ectopically expressing Spreds led to a decrease in cancer 
cell proliferation. This may be due to reduced ERK/MAPK 
activity [2, 16]. The underlying mechanism by which 
Spreds suppress tumor growth remains to be elucidated.
Macroautophagy (hereafter referred to as autophagy) 
is a conserved homeostatic mechanism of lysosomal 
degradation. The hallmark of autophagy is the formation 
of double- or multi-membrane vesicles in the cytosol called 
autophagosomes that encapsulate bulk cytoplasm and 
cytoplasmic organelles. These autophagosomes mature 
by fusing with the endocytic compartments (e.g. early and 
late endosomes, multivesicular bodies) and then fusing 
with the lysosomal compartment to form autolysosomes, 
in which the cargo is degraded by acidic lysosomal 
hydrolases [18, 19]. The process is tightly regulated by a 
set of core autophagy-related (ATG) proteins, including 
the ubiquitin-like modifier, ATG8. During autophagy, 
the microtubule-associated protein 1 light chain 3 (LC3), 
which is the mammalian homologue of yeast ATG8, is 
converted to lipidated LC3 II and associates with the 
autophagic membrane. The accumulation of LC3 II and its 
localization to the autophagosome (puncta dot formation) 
are generally used as markers for autophagy [20]. Lipidated 
LC3 II recruits receptors for specific cargo, such as p62 
(also known as SQSTM1) [21], neighbor of BRCA1 
(NBR1) [22–24] and adaptor proteins that modulate the 
movement and maturation of autophagosomes [25, 26]. All 
known autophagy receptor and adaptor proteins contain 
one or more LC3-interacting region (LIR) motif(s) with 
the consensus hydrophobic sequence W/Y/F-X-X-I/L/V 
[21, 27]. Recent studies have shown that several tumor 
suppressors, such as p53 and PTEN, may induce autophagy-
dependent cell death in tumor cells [28, 29], suggesting that 
autophagy modulation could be a critical mechanism for 
tumor suppression.
We previously reported that tyrosines 303/343/353 
at the SPR domain is essential for Spred2-mediated 
inhibition of tumor cell growth [8]. In this study, we 
show that Spred2 induces autophagy-associated tumor 
cell death by increasing autophagosome maturation. We 
further demonstrate that Spred2 enhances autophagosome-
lysosome fusion by binding to LC3 via two LIR motifs 
at the SPR domain. Importantly, both the functional LIR 
and Spred2-associated autophagy are required for Spred2 
to induce tumor cell death. Taken together, our study 
provides new insights into the underlying mechanisms by 
which Spred2 induces tumor cell death. 
RESULTS
Spred2 induces autophagy-associated tumor cell 
death
Using clone formation assays, we showed that 
infection with adenoviruses expressing Myc-tagged 
Spred2 (Ad-Spred2) results in the significant inhibition 
of colony formation in HeLa and A549 cells compared 
to control virus (Figure 1A), consistent with our previous 
work and others that Spred2 suppresses tumor cell growth 
[2, 8, 16]. To investigate whether apoptosis is involved 
in Spred2-induced tumor cell growth inhibition, HeLa 
cells infected with Ad-Spred2 were analyzed by flow 
cytometry using Annexin V and propidium iodide (PI) 
double-staining. Relative to control virus, Ad-Spred2 
infection increased the fraction of cells staining with 
Annexin V and PI at 24, 48 and 72 h, suggesting that 
Spred2 may induce apoptosis in these cells (Figure 1B). 
However, activation of Caspase-3 (effector of apoptosis) 
and cleavage of PARP (downstream target of active 
caspase-3) were not observed in Spred2-overexpressing 
HeLa cells as detected by immunoblotting (Figure 1C). 
As a positive control, Doxorubicin treatment induced 
marked cleavage of Caspase-3 and PARP (Figure 1C). 
Similar results were obtained in A549 cells (Figure S1A). 
Spred2 levels were modestly overexpressed in these lines 
by approximately 8-fold relative to the endogenous basal 
levels (Figure 1C and Figure S1A). Furthermore, Spred2-
induced HeLa cell death was not blocked by pre-treatment 
with the broad-specificity caspase inhibitor, Z-VAD-FMK 
(Figure 1D), which inhibited Doxorubicin-induced apoptosis 
(Figure S1B). This would suggest that Spred2-induced cell 
death may not be caspase-dependent. 
Given that autophagy plays a role in cell death 
triggered by tumor suppressors [28, 29], we hypothesized 
that Spred2 induces autophagy-associated cell death. To test 
this, we first examined whether Spred2 induces autophagy in 
tumor cells. Ultrastructural analysis by transmission electron 
microscope detected several degradative autophosomes in 
Ad-Spred2-infected HeLa cells which were rarely observed 
in HeLa cells infected with control virus (Figure 1E, arrow 
indicated). To confirm that the observed double-membraned 
vesicles were indeed related to autophagy, GFP-LC3 dot 
formation was investigated. Upon autophagy, LC3 is 
localized on autophagosomes and LC3 puncta are used 
as a marker for autophagosomes [30]. HeLa cells were 
co-transfected with GFP-LC3 and Myc-Spred2 or vector 
control. As depicted in Figure 1F, the number of cells with 
GFP-LC3 puncta in Spred2-overexpressing HeLa cells 
was higher than in control cells. Bafilomycin A1 (BafA1) 
is a specific inhibitor of the vacuolar type H+-ATPase 
(V-ATPase). This is known to block autophagosome-
lysosome fusion [31], leading to the accumulation of 
autophagic vacuoles, as demonstrated by a marked 
accumulation of LC3II. We observed that BafA1 treatment 
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further increased the number of cells with GFP-LC3 
puncta in Spred2-overexpressing HeLa cells (Figure 1F). 
Similar results were observed in HeLa cells treated with 
Rapamycin (Rapa), which selectively inhibits mTOR 
to simulate autophagy (Figure 1F) [30]. The autophagic 
substrate, p62, which is specifically degraded by the 
autophagic-lysosomal pathway, was widely used to monitor 
autophagy flux [32]. Unlike the control cells, in cells with 
suppressed autophagosome maturation (i.e., BafA1 treated 
cells) the loss of p62 upon treatment with Ad-Spred2 
was not apparent in HeLa and A549 cells (Figure 1G). 
This BafA1-dependent loss of p62 in response to Spred2 
indicates that exogenous Spred2 may activate the formation 
of autophagosomes rather than suppress their maturation.
To examine whether the autophagy induced by 
Spred2 serves as a pro-survival or pro-death mechanism, 
lentivirus expressing shRNA targeting ATG5 were used to 
stably knock down ATG5 in HeLa and A549 cells (HeLa/
shATG5 and A549/shATG5). Atg5 is a key molecule 
involved in autophagic vacuole formation, and the 
formation of the Atg12-Atg5 conjugate is indispensable 
to autophagosome formation. [33–35] So the autophagy 
process was blocked in ATG5-knockdown cells. 
Lentiviruses with control shRNA were used to establish the 
control cell lines (HeLa/shControl and A549/shControl). 
These cell lines were then infected with AdSpred2 and 
were analyzed by trypan blue dye exclusion. Spred2-
triggered cell death was reduced in HeLa/shATG5 cells 
compared with HeLa/shControl cells (Figure 1H). This 
observation was further confirmed by Annexin V and PI 
double-staining by flow cytometry (Figure 1I). Similar 
results were obtained in A549/shATG5 cells (Figure S1C 
and S1D). Depletion of ATG5 in HeLa and A549 cells was 
confirmed by immunoblotting (Figure 1J and Figure S1E). 
Consistently, pharmacological inhibition of autophagy by 
pretreatment with chloroquine (CQ), an autophagolysosome 
fusion inhibitor [30], attenuated Spred2-induced cell death 
in HeLa cells (Figure 1K). Together, these data indicate that 
inhibition of autophagy attenuates Spred2-mediated cell 
death in tumor cells.
Spred2 promotes autophagosome maturation in 
cancer cells
To elucidate the role of Spred2 in enhancing the 
autophagic process, we utilized a tandem fluorescent GFP-
mRFP-LC3 marker to analyze autophagosome maturation 
[36]. In this system, autophagosomes display both green 
and red fluorescence, while autolysosomes display 
only red fluorescence as the GFP loses its fluorescence 
from deprotonation in the acidic lysosomes. Therefore, 
autophagosomes appear as RFP+GFP+ (yellow dot) and 
mature, autolysosomal organelles appear as RFP+GFP- 
(red-only dot). Thus, autophagosome maturation can be 
indicated by a dramatic increase in the number of red-only 
autolysosomes [36]. HeLa cells were co-transfected with 
GFP-mRFP-LC3 and Myc-Spred2-WT or vector control. 
An increase in red-only dot was observed in HeLa cells 
transfected with Myc-Spred2 (Figure 2A). Moreover, in 
Spred2-overexpressing cells, treatment with Rapa resulted 
in a further increase in both yellow and red-only dot, 
whereas BafA1 treatment led to an increase in yellow 
dot and decrease in red-only dot (Figure 2A and 2B). In 
addition, we observed that BafA1-only or Rapa-only 
treatment increased the number of yellow dot in control 
HeLa cells (Figure 2A and 2B). As expected, treatment with 
Rapa induced an increase in the number of red-only dot in 
control HeLa cells (Figure 2A and 2B). These data suggest 
that overexpression of Spred2 enhances autophagosome 
maturation in HeLa cells.
To further establish the role of Spred2 in 
autophagosome maturation, Spred2 was knocked down by 
siRNA in HeLa cells and the efficiency was confirmed by 
immunoblotting (Figure 2C). To rule out the possibility of 
off-target effects, two independent siRNA oligonucleotides 
were used, both of which gave similar results. We observed 
the accumulation of both LC3 II and p62 in Spred2-
knockdown HeLa cells but not in control cells transfected 
with non-target siRNA, suggesting that Spred2 knockdown 
impaired autophagic degradation (Figure 2C and 2D). In 
addition, the effect of Spred2 knockdown on LC3 II and p62 
levels was rescued by expressing a Spred2 rescue plasmid 
(Figure 2C and 2D). We also found that Spred2 knockdown 
could inhibit the upregulation of autophagosome maturation 
induced by Rapa, which was reversed by the rescue Spred2 
expression plasmid (Figure 2E and 2F). This observation 
would indicate that Spred2 knockdown disrupted 
autophagosome maturation in cancer cells. Of note, loss of 
endogenous Spred2 abolished the ability of rapamycin to 
suppress p62 levels in HeLa cells (Figure 2G), suggesting 
that Spred2 promotes autophagosomes maturation. Above 
all, the effect of the autophagy modulators and Spred2 are 
shown in Table S2.
Spred2 co-localizes with autophagic organelles
The above findings that Spred2 enhances the 
autophagic process prompted us to explore how Spred2 
interacts with the autophagy machinery. We examined 
whether Spred2 co-localizes with autophagic organelles. 
ATG16L1 has been used to monitor the movement of plasma 
membrane as a donor for autophagy, and ATG16L1 is 
located on phagophores, but not completed autophagosomes.
[37, 38] No co-localization was observed between Myc-
tagged or endogenous Spred2 and endogenous ATG16L1 
in COS7 or HeLa cells. Similarly, CQ did not promote this 
co-localization (Figure S2A and S2B). However, confocal 
microscopy analysis revealed substantial co-localization of 
endogenous Spred2 and GFP-LC3 in cytoplasmic puncta in 
HeLa cells (Figure 3A). In addition, a similar co-localization 
of Myc-Spred2 with GFP-LC3 was also observed in HeLa 
cells (Figure 3B), indicating that Spred2 co-localizes with 
LC3. We also observed co-localization between Myc-Spred2 
and endogenous LAMP2 in HeLa cells (Figure 3C), a late 
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Figure 1: Spred2 triggers autophagy-associated tumor cell death. Cells were infected with adenoviruses expressing Myc-
Spred2-WT (AdSpred2-WT) or vector control (Ad-Vector) at a multiplicity of infection of 250 for 8 h (A, B, C, E). (A) HeLa and 
A549 cells were cultured in complete medium for 12 days during colony formation assays. (B) After 24, 48 or 72 h, HeLa cells were 
double stained with annexin V (AV) and propidium iodide (PI) for flow cytometric analysis (FACS). (C) Cell lysates were analyzed by 
immunoblotting with anti-Caspase-3, anti-PARP, anti-Spred2 and anti-GAPDH. Doxrubicin was used as a positive control. (D) HeLa cells 
were infected with AdSpred2-WT or Ad-Vector in the presence or absence of pan-caspase inhibitor (50 μM Z-VAD-FMK, Pan) for 24, 
48 and 72 h by FACS. (E) HeLa cells were examined by transmission electron microscopy (TEM). a, Untreated control HeLa cells showing 
normal distribution of organelles; b, HeLa cells infected with adenoviruses expressing Spred2. In the lower panels, typical structures 
enclosed in the black square have been enlarged for more detailed imaging; c, the degradation of the engulfed rough ER is advanced in 
this degradative autophagosome (indicated by black arrow); d, cup-shaped membranous structures and vacuoles present in the cytoplasm 
(indicated by black arrows). (F) HeLa cells were co-transfected with GFP-LC3 and vector or Myc-Spred2. These were then treated with 
Rapa (1 μM) or BafA1 (50 μM) for 4 or 24 h. The number of cells with GFP-LC3 punctate are represented. (G) HeLa and A549 cells 
were infected with Ad-vector or Ad-Spred2 and treated with BafA1 (50 μM). Cell lysates were analyzed by immunoblotting for LC3, p62, 
Spred2 and GAPDH protein expression. Hela/shControl or HeLa/shATG5 cells were infected with Ad-Vector or AdSpred2-WT as indicated 
for 8 h (H, I). (H) After 24, 48 and 72 h, cell death was determined using the trypan blue assay. (I) Cell death was determined by AV/PI 
double staining analysis. (J) Cell lysates from HeLa/shControl and HeLa/shATG5cells were analyzed by IB to determine the efficiency of 
ATG5 knockdown. (K) HeLa cells pre-treated with CQ were infected with Ad-Vector or AdSpred2-WT as indicated for 8 h. After 24, 48 and 
72 h, cell death was determined using the trypan blue assay. Data are represented as the mean ± S.D from three independent experiments 
(**p < 0.01, ***p < 0.001). 
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Figure 2: Spred2 enhances autophagosome maturation. (A) HeLa cells were co-transfected with GFP-mRFP-LC3 and vector 
or Myc-Spred2 and treated with or without Rapa (1 μM) or BafA1 (50 μM). Images were acquired by confocal microscope. The merged 
region enclosed within the white square has been enlarged in the right panel for clearer appreciation of these co-localizations. (B) The 
number of autophagosomes (yellow dots) and autolysosomes (red-only dots) per cell were quantified. HeLa cells were transfected with 
two siRNA duplexes targeted to Spred2 (siSpred2) or control siRNA (siControl) for 48 h (C, D, E, F,). (C) Cells were transfected with 
vector control or a Spred2 rescue plasmid (Rescue-Spred2). After 24 h, cell lysates were analyzed by immunoblotting for Spred2, LC3, 
p62 and β-actin protein expression. (D) The ratios of expression for each protein to their corresponding β-Actin are represented. (E) Cells 
were co-transfected with GFP-mRFP-LC3 and vector control or a Spred2 rescue plasmid for 24 h following Rapa-treatment for 4 h. 
Images were acquired by confocal microscopy. The merged region enclosed within the white square has been enlarged in the right panel 
for clearer appreciation of these co-localizations. Scale bars are representative of 50 μm. (F) The number of autophagosomes (yellow dots) 
and autolysosomes (red-only dots) per cell were quantified. (G) HeLa cells were transfected with two siRNA duplexes targeted to Spred2 
(siSpred2) or control siRNA (siControl) for 72 h. Cells were treated with or without Rapa (1 μM) for 4 h. Cell lysates were analyzed by 
immunoblotting for Spred2, LC3, p62 and β-Actin protein expression. The ratios of each specific protein to their corresponding β-Actin 
are represented. All quantitative data are represented as the mean ± S.D from three independent experiments (**p < 0.01, ***p < 0.001).
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endosomal/lysosomal marker that co-localizes with LC3 
during autophagsosome maturation [39]. These data indicate 
that Spred2 co-localizes with autophagic organelles. 
To examine the degree of overlap of Myc-Spred2 and 
GFP-LC3, each image from three distinct areas (regions 
of interest, ROIs) were sampled to correct background. 
Manders’ overlap coefficient (R) was employed to evaluate 
co-localization. An average of coefficients obtained 
from the examined field was calculated. Rapa treatment 
increased Myc-Spred2 and GFP-LC3 overlap, whereas 
treatment with CQ induced co-localization of Spred2 and 
LC3 on autophagic structures (Figure 3B). Similar results 
were obtained in COS7 cells (Figure S2C and S2D). These 
would suggest that the co-localization of Myc-Spred2 and 
GFP-LC3 were increased by autophagy modulators. 
Spred2 binds to LC3 via the LIR motifs in the 
SPR domain 
The observation of co-localization of Spred2 
with LC3 in autophagic organelles led us to speculate 
whether Spred2 binding to LC3. Endogenous Spred2 and 
endogenous LC3 were reciprocally immunoprecipitated in 
HeLa cells (Figure 4A and 4B). The interaction between 
Spred2 and LC3 was further demonstrated to be direct 
by in vitro pull-down assays with recombinant proteins 
(Figure 4C), supporting the existence of a Spred2-LC3 
interaction at physiological protein levels. 
To determine which domain of Spred2 is responsible 
for this binding, a series of Myc-tagged truncation 
constructs of Spred2, named Spred2-ΔEVH1, Spred2-
Figure 3: Spred2 localizes with LC3-positive autophagic structures. Cells were fixed and analyzed for co-localization by 
confocal microscopy. The merged region enclosed within the white square has been enlarged in the right panel for a clearer appreciation of 
the co-localizations. (A) HeLa cells overexpressing GFP-LC3 were analyzed for endogenous Spred2/GFP-LC3 co-localization. Scale bars 
are representative of 10 μm. (B) HeLa cells co-transfected with Myc-Spred2 and GFP-LC3 were treated with rapamycin (Rapa, 1 μM), CQ 
(50 μM), or vehicle control for 4 h. Cells were analyzed for Myc-Spred2/GFP-LC3 co-localization. The percentage of co-localization was 
quantified. Data are represented as mean ± S.D from three independent experiments (**p < 0.01). (C) Myc-Spred2/LAMP2 co-localization 
in HeLa cells overexpressing Myc-Spred2. Green staining, Myc-Spred2; red, total endogenous LAMP2 and blue staining for the cell 
nucleus. Scale bars are representative of 25 μm. 
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ΔKBD and Spred2-ΔSPR (Figure 4D), were prepared and 
used in co-immunoprecipitation (co-IP) assays. Further 
motif mapping revealed two potential LIR motifs in the 
SPR domain; W370XXL373and Y386XXL389 (Figure 4E). 
GFP-LC3 could be immunoprecipitated with Myc-Spred2 
in transfected 293T cells while the SPR domain of Spred2 
was the only LC3 binding region (Figure 4F). To determine 
whether these two LIR sequences in the SPR domain are 
required for Spred2 binding to LC3, W370, Y386, L373 
and L389 were all mutated to alanine (A). The resulting 
constructs were named as Spred2-W370A/L373A and 
Spred2-Y386A/L389A, respectively. Surprisingly, 
mutating either W370/L373 or Y386/L389 alone did not 
abolish Spred2 binding to LC3. However, four mutations 
of W370/L373 and Y386/L389 (Spred2- W370A/L373A/
Y386A/L389A, shown here as Spred2-AA), completely 
abrogated LC3 binding to Spred2 (Figure 4G). Similar data 
was observed in pull-down experiments by Myc-Spred2-
AA with GST-LC3 (Figure 4C), indicating that either LIR 
sequence in the SPR domain is sufficient for Spred2 binding 
to LC3. 
LIR motifs are required for Spred2-activated 
autophagosome-lysosome fusion
Next, we evaluated whether Spred2 binding to LC3 
is essential for its ability to promote autophagosome-
lysosome fusion. HeLa cells overexpressing Spred2-
WT, Spred2-ΔSPR, Spred2-AA or vector control with 
the tandem fluorescent GFP-mRFP-LC3 were examined 
for the level of autophagosome-lysosome fusion. Spred2 
overexpression increased the amount of red-only dot 
representing autolysosomes compared with vector control 
(Figure 5A). However, there was no change in the amount 
Figure 4: Functional LIR motifs in the SPR domain mediate Spred2/LC3 interaction. (A) HeLa whole-cell lysates (WCL) 
collected from 10 cm2 dishes were subjected to immunoprecipitation (IP) with an anti-LC3 antibody or an IgG control. (B) HeLa whole-cell 
lysates collected as A were subjected to IP using an anti-Spred2 antibody or an IgG control. (C) GST pull-down assays to analyze binding 
of an in vitro translated Myc-Spred2-WT or Myc-Spred2-AA (upper panel) against recombinant human GST-LC3 protein. The purified 
GST-alone and GST-LC3 protein used are displayed on the Coomassie-stained gels (bottom panel). (D) Schematic representation of the 
Spred2 domains. A series of Myc-tagged truncation constructs of Spred2 were named Spred2-ΔEVH1, Spred2-ΔKBD and Spred2-ΔSPR. 
(E) Sequence alignment of mutations in the SPR domain containing the LC3-interaction region (LIR) motifs (W370XXL373and Y386XXL389). 
Both tryptophan 370/leucine 373 and tyrosine 386/leucine 389 were mutated to Alanine and the resulting plasmids were subsequently 
named as Spred2-W370A/L373A and Spred2-Y386A/L389A, respectively. A four mutation of W370/L373 and Y386/L389 was created 
and named Spred2-W370A/L373A/Y386A/L389A, shown here as Spred2-AA. (F) 293T cells were co-transfected with GFP-LC3 and 
Myc-Spred2-WT or various Spred2 deletion constructs. (G) 293T cells were co-transfected with GFP-LC3 and Myc-Spred2-WT or Spred2 
mutants. (F, G) Whole-cell lysates (WCL) were IP with an anti-Myc antibody and proteins were resolved by IB. All experiments in this 
figure were performed as three independent experiments.
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of red-only dot in cells overexpressing Spred2-ΔSPR or 
Spred2-AA. Similar results were observed in A549 cells 
(Figure 5B). Together, these findings indicate that the 
LIR motifs in the SPR domain are essential for Spred2-
activated autophagosome-lysosome fusion. 
Spred2 interacts and co-localizes with p62
Previously, Heath and colleagues found that Myc-
Spred2 interacts with endogenous p62 in 293T cells [9]. 
Given that Spred2 promotes autolysosome formation, we 
examined whether p62 is involved in Spred2-mediated 
autolysosome formation. Endogenous p62 could be 
immunoprecipitated with endogenous Spred2 in HeLa 
cells (Figure 6A). In addition, Myc-Spred2 and Flag-p62 
were reciprocally immunoprecipitated in 293T cells 
(Figure 6B and Figure S3A). Furthermore, the binding 
of Spred2 with p62 in vivo was dependent on the SPR 
domain (Figure 6C), which was confirmed by co-
localization experiments (Figure S3B). Notably, Spred2-
AA mutant was able to bind and co-localize with p62 
in HeLa cells (Figures 6D and S3B). Interestingly, we 
observed co-localization among GFP-Spred2, endogenous 
p62 and endogenous LAMP2 in HeLa cells (Figure 6E). 
The co-localization of Myc-Spred2 and endogenous p62 
in HeLa cells was also observed (Figure 6F). This overlap 
was decreased by CQ or BafA1 (Figure 6F). However, 
the effect of Rapa on Spred2 and p62 co-localization was 
minimal (Figure 6F). These data indicate that Spred2 
interacts and co-localizes with p62 during the fusion 
of autophagosomes with lysosomes, a process that is 
sensitive to CQ and BafA1 treatment. 
Figure 5: LIR motifs are required for Spred2-mediated autophagosome-lysosome fusion. (A, B) HeLa cells (A) or A549 
cells (B) were co-transfected with vector, Myc-Spred2-WT, Myc-Spred2-ΔSPR or Myc-Spred2-AA and GFP-mRFP-LC3. Images of live 
cells were captured by confocal microscopy and the number of autophagosomes (yellow dots) and autolysosomes (red-only dots) per cell 
were quantified. The merged region enclosed in the white square has been enlarged on the right panel for a clearer appreciation of these 
co-localizations. Scale bars are representative of 50 or 25 μm. Data are represented as mean ± S.D from three independent experiments 
(***p < 0.001). 
Oncotarget25660www.impactjournals.com/oncotarget
LC3 contributes to the interaction and 
co-localization of Spred2 with p62
Based on our findings that LC3 is essential 
for Spred2-mediated promotion on autophagosome 
maturation, we hypothesized that LC3 is necessary for 
the binding of Spred2 with p62 during autolysosome 
formation. To test this hypothesis, Myc-Spred2 and 
FLAG-p62 were co-transfected in 293T cells with a 
stable depletion of LC3. Compared with control 293T 
cells, the binding of Spred2 with p62 was reduced in 
LC3-knockdown cells, as assayed by co-IP (Figure 7A). 
Figure 6: Spred2 interacts and co-localizes with p62. (A) HeLa whole-cell lysates collected from 10 cm2 dishes were subjected 
to IP with an anti-Spred2 antibody or an IgG control to detect endogenous Spred2 binding to endogenous p62. (B) 293T cells were co-
transfected with FLAG-p62 or vector, in addition to Myc-Spred2-WT or vector. (C) 293T cells were co-transfected with FLAG-p62 and 
Myc-Spred2-WT or various Spred2 deletion constructs. WCL were IP with an anti-FLAG antibody. (D) 293T cells were co-transfected 
with FLAG-p62 and Myc-Spred2-AA construct. (B, D) Whole-cell lysates (WCL) were IP with an anti-Myc antibody and were resolved by 
IB. (E) HeLa cells were transfected with GFP-Spred2. The co-localization of GFP-Spred2, endogenous LAMP2 and endogenous p62 was 
detected. The merged region enclosed within the white square has been enlarged in the bottom panel for better appreciation and the arrows 
indicate the regions of merge. (F) HeLa cells overexpressing Myc-Spred2 were either untreated or treated with Rapa (1 μM), CQ (50 μM) 
or BafA1 (50 μM) for 4 h. Myc-Spred2/endogenous p62 co-localization was detected. The merged region enclosed within the white square 
has been enlarged in the right panel for clearer appreciation and the arrows indicate the regions of merge. Scale bars are representative of 
25 μm. All experiments in this figure were performed as three independent experiments.
Oncotarget25661www.impactjournals.com/oncotarget
Consistently, the co-localization of Myc-Spred2 and 
endogenous p62 was decreased in HeLa cells with a 
stable depletion of LC3 compared to control cells (Figure 
7B). Inducing autophagy with Rapa did not increase the 
co-localization of Spred2 and p62 in cells depleted of LC3 
(Figure 7B). LC3 protein expression in HeLa cells was 
determined by immunoblotting (Figure 7C). These results 
suggest that LC3 is essential for Spred2 interaction and 
co-localization with p62.
Abolishment of the association of Spred2 with 
LC3 and depletion of LC3 or p62 impedes 
Spred2-mediated tumor cell death
Given that Spred2 interacts with LC3 and contributes 
to Spred2-mediated autophagy, we investigated whether the 
interaction between Spred2 and LC3 is essential for Spred2-
induced autophagy-associated cell death. HeLa cells were 
infected with adenoviruses expressing Myc-Spred2-WT, 
Myc-Spred2-ΔSPR, Myc-Spred2-AA (LC3 mutated 
binding sites) or an empty vector control. The cells were 
then subjected to either a clone formation assay or trypan 
blue dye exclusion analysis. AdSpred2 infection resulted in 
the formation of fewer colonies and more dead cells relative 
to the control virus, AdSpred2-ΔSPR and AdSpred2-
AA (Figure 8A and 8B), indicating a role of the LIR in 
Spred2-induced cancer cell death. The protein levels of 
these adenoviruses were validated by immunoblot analysis 
(Figure 8B). To further assess the extent to which the 
observed cell death depends on autophagy, trypan blue dye 
exclusion experiments were performed in LC3-knockdown 
or p62-knockdown HeLa and control cells, infected 
with AdSpred2 or control virus, respectively. Following 
AdSpred2 infection, fewer dead cells were detected in 
Figure 7: LC3 is essential for Spred2 interaction and co-localization with p62. (A) 293T cells with a stable knockdown of LC3 
(293T/shLC3) and control cells (293T/shControl) were co-transfected with Myc-Spred2 and FLAG-p62. Whole-cell lysates (WCL) were 
IP with anti-Myc and resolved by IB. LC3 and GAPDH protein expression in response to LC3 knockdown was determined. (B) HeLa cells 
with a stable knockdown of LC3 (HeLa/shLC3) and control (HeLa/shControl) cells were transfected with Myc-Spred2 and treated with 
Rapa (1 μM) for 4 h. The co-localization of Myc-Spred2 and endogenous p62 was detected. The merged region enclosed within the white 
square has been enlarged in the right panel for clearer appreciation and the arrows indicate the regions of merge. Scale bars are represented 
as 25 μm. (C) Cell lysates of HeLa/shLC3 cells and HeLa/shControl cells were analyzed by IB to determine the efficiency of the LC3 
knockdown. All experiments in this figure were performed as three independent experiments. 
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p62-knockdown or LC3-knockdown HeLa cells than 
in control cells (Figure 8C and 8D). We observed 
similar results in p62-knockdown or LC3-knockdown 
A549 cells (Figure S4A and S4B). The efficiency of LC3 
or p62 knockdown in HeLa and A549 cells was examined 
respectively by immunoblotting (Figures 8E, 8F, S4C 
and S4D). Both LC3 and p62 were essential for Spred2-
mediated cell death. Together, these data along with results 
from Figure 1H and Figure 1I, suggest that autophagy 
contributes to Spred2- induced tumor cell death. 
Figure 8: Abolishing the association of Spred2 with LC3 and depletion of LC3 or p62 impedes Spred2-mediated tumor 
cell death. (A, B) Cells were infected with adenoviruses expressing Myc-Spred2-WT (AdSpred2-WT), Myc-Spred2-ΔSPR (AdSpred2-
ΔSPR), Myc-Spred2-AA (AdSpred2-AA) or vector control (Ad-Vector) at a multiplicity of infection of 250 for 8 h. (A) HeLa cells were 
cultured in complete medium for 12 days during colony formation assays. The graph represents the number of colonies present in the plate 
at the end of this time. (B) Cell death was determined by cell counting using trypan blue exclusion staining of HeLa cells. Expression 
in response to the overexpression of constructs was also examined by IB. (C, D) Cells with a stable knockdown of LC3 (HeLa/shLC3), 
p62 (HeLa/shp62) or control cells (HeLa/shControl) were infected with adenoviruses expressing Myc-Spred2-WT or vector control at a 
multiplicity of infection of 250 for 8 h. HeLa/shControl or HeLa/shLC3 cells (C) and HeLa/shControl or HeLa/shp62 (D) were determined 
by cell counting using trypan blue exclusion staining for cell death analysis. (E, F) Cell lysates of HeLa/shLC3 cells or HeLa/shControl 
cells (E) and HeLa/shp62 cells or HeLa/shControl cells (F) were analyzed by IB to determine the efficiency of LC3 or p62 knockdown. Data 
are represented as mean ± S.D from three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001).
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DISCUSSION
Collectively, our results indicate that Spred2 triggers 
tumor cell death in an autophagy-dependent manner. We 
demonstrate that Spred2 induces autophagy and enhances 
autophagosome maturation in tumor cells. Mechanistically, 
Spred2 interacts and co-localizes with LC3 via the LIR 
motifs in the SPR domain, while the functional LIR motifs 
mediate Spred2-associated autophagosome maturation and 
contribute to Spred2-induced tumor cell death. In addition, 
Spred2 interacts and co-localizes with p62 and depletion 
of p62 in tumor cells, attenuating Spred2-triggered cell 
death. Together, our data uncover a novel mechanism by 
which Spred2 exhibits its tumor suppressor function.
To our knowledge, this is the first report showing 
that autophagy is involved in Spreds-mediated tumor 
cell death. Our results demonstrated that Spred2, a 
tumor suppressor, enhances the autophagic process in 
cancer cells by increasing autophagosome maturation. 
Furthermore, knockdown of Spred2 impairs the autophagy 
flux and the autophagy inducer Rapamycin, has no effect 
on Spred2 knockdown-induced p62 accumulation in 
cancer cells. These observations indicate that endogenous 
Spred2 promotes autophagic degradation. Moreover, 
pharmacological inhibition of autophagy and knockdown of 
the key autophagy-related genes decreases Spred2-induced 
cancer cell death, indicating that Spred2 triggers cancer cell 
death in an autophagy-dependent manner.
We also provide insights into the molecular 
mechanism by which Spred2 enhances autophagosome 
maturation. Specifically, our results underline the 
importance of the interaction of Spred2 with LC3 via the 
two LIR motifs in the SPR domain. Mutations in the LIR 
motifs decreased the number of red-only autolysosomes, 
thereby impairing the autophagosome-lysosome fusion. 
Previous studies have reported an interaction between 
Spred2 and p62 [9]. We further demonstrate that the SPR 
domain mediates the binding and co-localization of Spred2 
with p62. Consistent with previous findings by Mardakheh 
et al. [9], we observed that Myc-tagged-Spred2-ΔSPR 
was mainly localized in the nucleus of cancer cells, while 
the majority of myc-Spred2 in these cells exhibited a 
puncta cytoplasmic staining. It is possible that the nuclear 
localization of Spred2-ΔSPR is either the reason or the 
consequence of the lacking interaction with autophagosome 
components. Notably, we found that Spred2 interaction and 
co-localization with p62 is dependent on the Spred2/LC3 
interaction. Spred2 is also shown to interact with NBR1 
and of interest, co-localizes with NBR1 and p62 [9]. Both 
NBR1 and p62 are selective autophagy substrates and 
receptors that bind to LC3 via their LIR motifs. Based on 
our observations that Spred2 interacts and co-localizes with 
LC3 and p62, our data suggest that Spred2 is a scaffold 
protein in autophagosome maturation. 
Spred2 functions as a tumor suppressor in a variety 
of cancers. Decreased expression of Spred2 is observed 
in hepatocellular carcinoma and prostate cancer [15, 16], 
while forced Spred2 expression suppresses cell growth in 
a variety of tumor cells [15–17]. We recently reported that 
forced expression of Spred2 inhibits HeLa cell growth while 
deletion of the SPR domain attenuates this inhibitory effect 
[8]. In the present study, we show that Spred2-associated 
autophagy can induce tumor cell death. This notion was 
further supported by our observation that Spred2-mediated 
tumor cell death was impaired by either mutations in the 
LIR motifs in Spred2 or knockdown of ATG5, LC3 or 
p62. Several reports have shown that tumor suppressors 
trigger autophagy-dependent cell death [28, 29, 40]. 
In a study by Seillier et al, the tumor suppressor protein 
53-induced nuclear protein 1 (TP53INP1), was shown to 
bind to LC3 through the LIR and promotes autophagy-
dependent tumor cell death [40]. The tumor suppressor 
p53 also induces autophagic cell death in cancer cells [41]. 
These data together with our findings, suggest that the 
autophagy process promoted by tumor suppressors, may be 
a mechanism in tumor suppression. 
Taken together, this study demonstrates that 
through its interaction with LC3, Spred2 enhances 
autophagosome maturation thereby contributing to tumor 
cell death. Our study also suggests that autophagy may 
be a potential target for enhancing Spred2-mediated anti-
tumor activity. 
MATERIALS AND METHODS
Cell culture and transfection
Human embryonic kidney cells (293T), monkey 
fibroblast-like kidney cells (COS7), human cervical 
carcinoma cells (HeLa) and human lung cancer cells (A549) 
were purchased from American Type Culture Collection 
(ATCC). 293T, COS7 and A549 cell lines were cultured 
in DMEM (Gibco) supplemented with 10% fetal bovine 
serum (FBS) and HeLa cells were cultured in MEM (Gibco) 
supplemented with 10% FBS. All cells were cultured in a 
humidified incubator under 5% CO2 at 37°C. Transfection 
of plasmids into all cells (for immunoprecipitation or 
immunofluorescence) was performed using Lipofectamine 
2000 (Invitrogen), according to the manufacturer’s 
instructions. 
Antibodies and reagents
For a list of antibodies, see Table S1. Bafilomycin 
A1 (BafA1) was purchased from Merck Millipore. 
Doxorubicin (Dox), Chloroquine (CQ) and Rapamycin 
(Rapa) were purchased from Sigma and diluted in 
dimethyl sulfoxide (DMSO). The caspase inhibitor 
Z-VAD-FMK (Pan) was purchased from Selleckchem. 
Small interfering RNA (siRNA) against Spred2 and 
non-targeting siRNA controls were obtained from 
Qiagen. 
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Immunoprecipitation and immunoblotting
Immunoprecipitation (IP) and immunoblotting (IB) 
were performed as previously described [42]. In some 
cases, membranes were stripped and re-probed with 
specific antibodies. To quantify changes, the densitometries 
of protein bands were determined with a calibrated GS-
670 densitometer. For endogenous interactions, HeLa cells 
grown in 10 cm2 dishes were harvested and the cell lysates 
were then subjected to IP. All IP and IB experiments were 
performed as three independent experiments.
GST-pull down assays
GST-tagged-LC3 protein was expressed in 
Escherichia coli SoluBL21. Expression was induced by 
addition of 0.5 mM IPTG and cells were incubated at 20°C 
overnight. Collected cells were lysed using sonication 
in buffer (20 mM Tris-HCl at pH 7.5, 10 mM EDTA, 
5 mM EGTA and 150 mM NaCl). GST fusion protein 
was purified on glutathione-Sepharose 4 Fast Flow beads 
(GE Healthcare). For GST pull-down using cell lysates, 
293T cells were transfected with Myc-Spred2 using 
transfection reagent (Lipofectamine 2000, Invitrogen). Cells 
were lysed and were incubated with GST-LC3 protein on 
glutathione-Sepharose beads in binding buffer (50 mM 
Tris, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40, pH 8.0,) 
supplemented with protease inhibitor for 1 h at 4°C. 
Following five washes, the beads and precipitated proteins 
were eluted with 5 × SDS-PAGE loading buffer, boiled and 
loaded on SDS-PAGE gels for analysis.
Plasmids, adenovirus and lentivirus
Myc-tagged Spred2 and deletion mutants (ΔEVH1, 
ΔKBD and ΔSPR) were kindly provided by Prof. John 
K Heath. Mutations for tryptophan 370/leucine 373 and 
tyrosine 386/leucine 389 were mutated to Alanine in Spred2 
and introduced by PCR-based site-directed mutagenesis. The 
resulting construct was named Spred2-AA. The GFP-tagged 
Spred2 was constructed per standard molecular cloning 
procedures. FLAG-tagged p62 was kindly provided by Prof. 
Haining Zhu. mRFP-GFP-tagged LC3 was kindly provided 
by Yoshimori [43]. GFP-tagged LC3 was purchased from 
Addgene. Adenoviruses expressing Myc-tagged Spred2 
and Myc-tagged Spred2-ΔSPR and the control virus (Ad-
Vector) were previously described [8]. The AdEasy XL 
adenoviral vector system (Stratagene) was used to generate 
adenovirus-Myc-Spred2-AA. Primers used were as follows: 
5′-GGGGTACCATGACCGAAGAAACACACC-3′ and 
5′-GCCAAGCTTATGGTGATGGTGATGATG-3′. The 
following lentiviral constructs were purchased from Santa 
Cruz: p62 (SQSTM1) shRNA (sc-29679-V), ATG5 shRNA 
(sc-41445-V), MAP LC3β shRNA (sc-43390-V) and non-
coding shRNA (sc-108080). Lentiviral particles were used 
to directly infect 293T, A549 and HeLa cells. Stable clones 
were then selected using puromycin (Sigma). The selected 
cell populations were subjected to immunoblotting to 
investigate the silencing efficiency.
RNA interference
RNA interference was used to knock down targeted 
proteins of interest. Two siRNA oligonucleotides were 
used for Spred2: 5′-AAGGACTTGGTCTACACCAAA-3′ 
and 5′-CAGACCCTTGCTCGTGCGATA-3′. Transfection 
of siRNA was performed as previously described [42]. A 
scrambled siRNA was used as a negative control and the 
silencing efficiency was detected by immunoblot analysis. 
A Myc-tagged Spred2 rescue plasmid was generated by 
creating three silent base-pair mutations in the wild type 
sequence [44].
Transmission electron microscopy
For ultrastructural analysis, standard transmission 
electron microscopy (TEM) was carried out. Adenovirus 
infection was performed as above. Four hours after 
infection, the cells were fixed and embedded. Thin sections 
(90 nm) were cut and examined at 80 kV with a JEOL 
1200EX transmission electron microscope. Approximately 
15 cells were counted and autophagosomes were defined 
as structures measuring 0.5 to 2.0 μm.
Fluorescence microscopy and indirect 
immunofluorescence 
For fluorescence microscopy, HeLa cells were 
transfected with GFP-tagged LC3 using Lipofectamine 
2000. Dot formation by GFP-LC3 was detected with a 
fluorescence microscope (Olympus IX81) as previously 
described [45]. Transfected cells with five or more puncta 
were considered to have accumulated autophagosomes. A 
total of 100 transfected cells were examined per well, in 
triplicate, from three independent experiments.
For immunofluorescence microscopy, cells were 
plated on coverslips (NEST, 801008) 24–48 h before 
immunostaining. Cells were washed twice with ice-cold PBS 
and were fixed in 4% paraformaldehyde (PFA) for 30 min, 
permeabilized in 0.2% Triton X-100 for 15 min and 
incubated for 60 min in 3% Bovine Serum Albumin (BSA). 
Cells were then incubated with primary antibody overnight 
followed by a secondary antibody in PBS containing 3% 
BSA. Nuclei were stained with 5 μg/mL DAPI (Sigma) in 
PBS. Images were acquired using a confocal microscope 
(Leica TCS SP5 ×) with a 60 × oil objective. Images from 
each experiment were acquired using the same exposure 
time during the same imaging session. Quantification 
of autophagic vacuoles was analyzed by calculating the 
number of LC3 puncta from three fields containing more 
than 5 randomly selected microscopy-captured images, 
each comprising between 2 and 8 cells. Autophagosomes 
were detected as RFP+GFP+ (yellow dot), while mature, 
autolysosomal organelles were detected as RFP+GFP- 
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(red-only dot) [46–48]. To examine the degree of overlap 
of red (Myc-Spred2) and green (GFP-LC3) spots, analysis 
of pixel co-localization was performed using the co-
localization function of Image-Pro Plus software. The gain 
and offset were lowered to prevent saturation in the brightest 
signals. From each image three distinct areas (regions of 
interest, ROIs) were sampled to correct for background. 
Manders’ overlap coefficient (R) was employed to evaluate 
co-localization, and therefore could be used to determine 
the co-localization of two signals. The values of Manders’ 
overlap co-efficientare are in the range of 0 to 1.0. If the 
image has an overlap coefficient of 1, it implies that 100% 
of both selected channels overlap or co-localize. A value 
of zero means that there are no overlapping pixels. It can 
be used in any co-localization experiment. To assess the 
reliability of this method, we applied the same procedure 
to HeLa and COS7 cells for the co-localization of Myc-
Spred2 and GFP-LC3. Quantification of the co-localization 
was analyzed from three fields containing more than 
5 randomly selected microscopy-captured images, each 
of which comprised at least two cells. For each area an 
average of coefficients obtained from the examined field 
was calculated. The t-test was used to assess the results [49].
Flow cytometry analysis of apoptosis
Apoptosis was determined by flow cytometric 
analysis of membrane re-distribution of phosphatidylserine 
using Annexin V and propidium iodide (PI) double-
staining technique. The cell population in the upper 
right and lower right quadrants (Annexin V-positive/PI-
positive and Annexin V-positive/PI-negative, respectively) 
corresponds to apoptotic cells. The percentage of apoptotic 
cells was determined in three independent experiments.
Trypan blue exclusion assay
Cells were seeded at 3 × 104 cells/well in 12-well 
plates. The following day, cells were infected with 
adenoviruses at a multiplicity of infection (MOI) of 250. 
The trypan blue exclusion assay was performed to 
determine the level of cell death as previously described [8]. 
Experiments were repeated at least three times.
Colony formation assay
Cells were cultured in complete medium 
supplemented with 10% FBS at 37°C in 5% CO2. The 
colonies (containing 50 or more cells) were counted by 
light microscopy after 12 days. All semi-solid cultures were 
performed in triplicate. Three independent experiments 
were performed.
Statistical analysis 
Data were first evaluated using one-way analysis 
of variance (ANOVA). Multiple comparisons between 
treatment groups and controls were performed using 
Dunnett’s least significant difference (LSD) test. Statistical 
significance between groups was calculated using the LSD 
test in SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). 
A value of p < 0.05 was considered statistically significant.
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